Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Genomic Alterations in Inflammatory Breast Ca

Is there opportunity for targeted therapy?

Comprehensive genomic profiling uncovered a high frequency of genomic alterations (GA) in inflammatory breast cancer (IBC), with 96% of cases involving at least 1 clinically relevant genomic alteration, according to a study of 53 IBC formalin-fixed paraffin-embedded specimens taken from a series of 2,208 clinical cases of advanced/refractory invasive breast cancers. CRGA was defined as GA associated with on-label targeted therapies and targeted therapies in mechanism-driven clinical trials. Researchers found:

• 39% of IBCs were triple negative breast cancer (ER-/PR-/HER2).

• 25% were HER2+ with complete concordance with ERBB2 amplification detected by the CGP assay.

• At least 1 alteration associated with an FDA-approved therapy or clinical trial was identified in 96% of cases.

Citation: Ross JS, Ali SM, Wang K, et al. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Res Treat. 2015;154(1):155-162. doi:10.​1007/​s10549-015-3592-z.